An immunotherapy drug called Tecentriq (atezolizumab) extended the survival of lung cancer patients for several months longer than chemotherapy and caused fewer side effects, according to a new study.
The findings are from an early analysis of 850 patients with non-small cell lung cancer in a phase 3 trial funded by the drug’s makers.
According to the American Cancer Society, non-small cell lung cancer is the major form of the disease, comprising up to 85 percent of cases. Lung cancer remains the leading cancer killer in the United States, with more than 158,000 people expected to die from the disease this year.
The patients in the new trial had run out of treatment options. They received either Tecentriq or the chemotherapy drug docetaxel — the standard treatment for this type of cancer.
Click here to Read the full article: Immune-Focused Drug Shows Promise Against Lung Cancer
Share this entry
- The American Health Council Welcomes Hartmuth B. Bittner, MD, Ph.D., FACS to its Board of Physicians September 19, 2018
- Valeria Robinson-Baker, B.S.Pharm., R.Ph., C.Ph., is Appointed to the American Health Council’s Industry Board September 18, 2018
- The American Health Council Names Norman Tomaka, BS, Pharm.MS, FAPhA to its Industry Board September 10, 2018
- Samuel Ashu, Pharm.D., is Elected to the American Health Council’s Industry Board September 7, 2018
- Erin Engel, DPM is Appointed to the American Health Council’s Board of Physicians August 28, 2018
- Brittany Bento, PA-C is Appointed to the American Health Council’s Board of Physicians August 27, 2018